MS organizations have estimated that 2.3 million people are living with MS worldwide. Globally, the median estimated prevalence of MS is 112.0 per 100000 and the median estimated incidence of MS is 5.2 per 100000. Iran is considered as a country with highest MS prevalence (51.52 per 100000) in Middle East.
Cardiovascular disease (CVD) is the leading cause of death in Iran. Because of growing and aging population, the burden of CVD will increase steeply in Iran during 2005–2025, even if the epidemiological factors do not decrease during that period. In addition, the highest disease burden will persist in the working age (<65 yr).
The 2013 International Federation of Diabetes (IDF) Atlas for Diabetes ranked the Middle East and North Africa (MENA) with the highest worldwide prevalence of diabetes at 10.9%. Iran is one of the 19 countries and territories of the IDF MENA region. 425 million people have diabetes in the world and more than 39 million people in the MENA Region; by 2045 this will rise to 67 million. There were 4.985.500 cases of diabetes in Iran in 2017 . The Iranian Diabetes Society (IDS) has formally been founded in 1968 in Tehran. Now IDS has more than 20 branches in different cities of Iran. More than 100,000 diabetics registered as members of IDS in different branches. The aim of IDS is to raise awareness of Iranian society through education for public, diabetics, health care providers and policy makers.
Iran as the most populated country in the Middle East with a population of about ~82 million is the 18th largest population in the world. Iran is also a developing country with a high rate of consanguineous marriages, and thereby has a significant number of patients affected with some rare bleeding disorders. Recently, the Ministry of Health in Iran has established a national registry of bleeding disorders in the country. Although this program is still in the early stage, it can be helpful in better understanding and management of patients with RDBs.
1.HemophiliaBased on population, Iran has one of the highest global incidences in hemophilia. A survey by World Federation of Hemophilia (WFH) in 2014, in 107 countries, identified 176 211 people with hemophilia (A and B), 140 313 of whom had HA. According to this survey, Iran, with 5369 patients, has the ninth largest hemophilia population, in 2014, 4438 had HA and 931 had HB.
2.von Willebrand diseaseBased on the Iranian Hemophilia Society (HIS) report, the total number of patients with hemostatic disorders in Iran is 10,944 (a prevalence of 131 per million), while the number of registered patients with VWD is 1,617 and 1,516 according to the IHS and annual global survey report of World Federation of Hemophilia (WFH), respectively (a prevalence of ~19 per million). Due to high rate of consanguineous marriage and autosomal recessive inheritance pattern of type 3, the prevalence of type 3 is around 4 per million in Iran, which overshadows that of Western European countries with a reported prevalence of ~0.45 per million.
3.Factor XIII DeficiencyOwing to a high rate of consanguineous marriages, Iran has an extremely high prevalence of FXIIID, approximately 12-fold higher than the overall frequency in the rest of the world, with southeastern Iran showing the highest prevalence of FXIIID worldwide.
6.Factor II deficiency
7.Factor V deficiency
8.Factor V+VIII deficiency
9.Factor VII deficiency
10.Factor X deficiency
11.Factor XI deficiency
12.Factor XII deficiency
13.II + VII + IX + X deficiency
15.VII + XI deficiency